Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bednarz

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2015
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell CarcinomaToni M Brand, Mari Iida, Andrew P Stein, et al.
Radiation Research|April 7, 2021
Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the BrainPaul A Clark, Raghava N Sriramaneni, Amber M Bates, et al.
Theranostics|May 17, 2021
Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapyJustin C Jagodinsky, Won Jong Jin, Amber M Bates, et al.
Radiation Research|March 25, 2026
Enhanced Response to Radiopharmaceutical Therapy in Preclinical Tumor Models with XRD-0394, a Dual Inhibitor of ATM Kinase and DNA-PKcsCaroline P Kerr, Won Jong Jin, Alejandro J Oñate, et al.
Nature Communications|January 26, 2026
Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in miceCaroline P Kerr, Won Jong Jin, Peng Liu, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Priming versus propagating: distinct immune effects of an alpha- versus beta-particle emitting radiopharmaceutical when combined with immune checkpoint inhibitionCaroline P Kerr, Won Jong Jin, Peng Liu, et al.
Biorxiv : the Preprint Server for Biology|July 29, 2024
Effects of clinically relevant radionuclides on the activation of a type I interferon response by radiopharmaceuticals in syngeneic murine tumor modelsCaroline P Kerr, Julia Sheehan-Klenk, Joseph J Grudzinski, et al.
Cancer Immunology Research|May 29, 2025
The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor EfficacyCaroline P Kerr, Julia Sheehan-Klenk, Joseph J Grudzinski, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2015
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell CarcinomaToni M Brand, Mari Iida, Andrew P Stein, et al.
Radiation Research|April 7, 2021
Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the BrainPaul A Clark, Raghava N Sriramaneni, Amber M Bates, et al.
Theranostics|May 17, 2021
Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapyJustin C Jagodinsky, Won Jong Jin, Amber M Bates, et al.
Radiation Research|March 25, 2026
Enhanced Response to Radiopharmaceutical Therapy in Preclinical Tumor Models with XRD-0394, a Dual Inhibitor of ATM Kinase and DNA-PKcsCaroline P Kerr, Won Jong Jin, Alejandro J Oñate, et al.
Nature Communications|January 26, 2026
Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in miceCaroline P Kerr, Won Jong Jin, Peng Liu, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Priming versus propagating: distinct immune effects of an alpha- versus beta-particle emitting radiopharmaceutical when combined with immune checkpoint inhibitionCaroline P Kerr, Won Jong Jin, Peng Liu, et al.
Biorxiv : the Preprint Server for Biology|July 29, 2024
Effects of clinically relevant radionuclides on the activation of a type I interferon response by radiopharmaceuticals in syngeneic murine tumor modelsCaroline P Kerr, Julia Sheehan-Klenk, Joseph J Grudzinski, et al.
Cancer Immunology Research|May 29, 2025
The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor EfficacyCaroline P Kerr, Julia Sheehan-Klenk, Joseph J Grudzinski, et al.
Pageof 6